Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29,441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer.
Tien JC, Chugh S, Goodrum AE, Cheng Y, Mannan R, Zhang Y, Wang L, Dommeti VL, Wang X, Xu A, Hon J, Kenum C, Su F, Wang R, Cao X, Shankar S, Chinnaiyan AM. Tien JC, et al. Among authors: cheng y. Proc Natl Acad Sci U S A. 2021 May 18;118(20):e2026104118. doi: 10.1073/pnas.2026104118. Proc Natl Acad Sci U S A. 2021. PMID: 33972443 Free PMC article.
Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2.
Qiao Y, Wang XM, Mannan R, Pitchiaya S, Zhang Y, Wotring JW, Xiao L, Robinson DR, Wu YM, Tien JC, Cao X, Simko SA, Apel IJ, Bawa P, Kregel S, Narayanan SP, Raskind G, Ellison SJ, Parolia A, Zelenka-Wang S, McMurry L, Su F, Wang R, Cheng Y, Delekta AD, Mei Z, Pretto CD, Wang S, Mehra R, Sexton JZ, Chinnaiyan AM. Qiao Y, et al. Among authors: cheng y. Proc Natl Acad Sci U S A. 2021 Jan 5;118(1):e2021450118. doi: 10.1073/pnas.2021450118. Epub 2020 Dec 28. Proc Natl Acad Sci U S A. 2021. PMID: 33310900 Free PMC article.
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
Yang J, Chang Y, Tien JC, Wang Z, Zhou Y, Zhang P, Huang W, Vo J, Apel IJ, Wang C, Zeng VZ, Cheng Y, Li S, Wang GX, Chinnaiyan AM, Ding K. Yang J, et al. Among authors: cheng y. J Med Chem. 2022 Aug 25;65(16):11066-11083. doi: 10.1021/acs.jmedchem.2c00384. Epub 2022 Aug 8. J Med Chem. 2022. PMID: 35938508 Free PMC article.
CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
Tien JC, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, Yang J, Mannan R, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Lord CJ, Ding K, Chinnaiyan AM. Tien JC, et al. Among authors: cheng y, cheng c. bioRxiv [Preprint]. 2024 Mar 21:2024.03.20.585990. doi: 10.1101/2024.03.20.585990. bioRxiv. 2024. Update in: Cell Rep Med. 2024 Oct 15;5(10):101758. doi: 10.1016/j.xcrm.2024.101758 PMID: 38562774 Free PMC article. Updated. Preprint.
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J, Chen Z, Qiao Y, Tien JC, Young E, Mannan R, Mahapatra S, He T, Eyunni S, Zhang Y, Zheng Y, Su F, Cao X, Wang R, Cheng Y, Seri R, George J, Shahine M, Miner SJ, Vaishampayan U, Wang M, Wang S, Parolia A, Chinnaiyan AM. Luo J, et al. Among authors: cheng y. bioRxiv [Preprint]. 2024 May 23:2024.03.29.587346. doi: 10.1101/2024.03.29.587346. bioRxiv. 2024. PMID: 38586029 Free PMC article. Preprint.
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition.
Chang Y, Wang X, Yang J, Tien JC, Mannan R, Cruz G, Zhang Y, Vo JN, Magnuson B, Mahapatra S, Cho H, Dhanasekaran SM, Wang C, Wang Z, Zhou L, Zhou K, Zhou Y, Zhang P, Huang W, Xiao L, Liu WR, Hamadeh R, Su F, Wang R, Miner SJ, Cao X, Cheng Y, Mehra R, Ding K, Chinnaiyan AM. Chang Y, et al. Among authors: cheng y. Cell Rep Med. 2024 Oct 15;5(10):101752. doi: 10.1016/j.xcrm.2024.101752. Epub 2024 Sep 30. Cell Rep Med. 2024. PMID: 39353441 Free PMC article.
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.
Tien JC, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, Yang J, Mannan R, Mahapatra S, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Chou J, Lord CJ, Ding K, Chinnaiyan AM. Tien JC, et al. Among authors: cheng y, cheng c. Cell Rep Med. 2024 Oct 15;5(10):101758. doi: 10.1016/j.xcrm.2024.101758. Epub 2024 Oct 4. Cell Rep Med. 2024. PMID: 39368479 Free PMC article.
29,441 results
You have reached the last available page of results. Please see the User Guide for more information.